Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1

BACKGROUND: Arsenic trioxide (ATO) is commonly used in the treatment of acute promyelocytic leukemia (APL), but does not benefit patients with solid tumors. When combined with other agents or radiation, ATO showed treatment benefits with manageable toxicity. Previously, we reported that metformin am...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Sunbin, Xie, Haiyang, Yang, Fan, Shan, Qiaonan, Dai, Haojiang, Zhuo, Jianyong, Wei, Xuyong, Song, Penghong, Zhou, Lin, Xu, Xiao, Zheng, Shusen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329912/
https://www.ncbi.nlm.nih.gov/pubmed/28241849
http://dx.doi.org/10.1186/s13045-017-0424-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329912/
https://www.ncbi.nlm.nih.gov/pubmed/28241849
http://dx.doi.org/10.1186/s13045-017-0424-0

Ejemplares similares